April 2012
Digital Edition
Digital Compendium
March 2012
February 2012
Digital Edition
Trailblazer Awards
2011 Digital Edition
Product Manager
Survey Supplement
August 2011
Digital Edition
![]() |
| Anna Stashower President/Publisher Welcome to PM360 |
|
COMMON SENSE By Bud Bilanich |
![]() |
| Tweets to Live By |
Join us next year and we along with the industry will see you Here.
![]() |
Copay Coupons: Should They Stay or Should They Go? Community Catalyst has laid out its case for why copay coupons should be illegal. Now pharma, doctors, pharmaceutical consulting groups, and others weigh in on whether these coupons really will lead to more harm than good. Read more. |
|
|
Washington Wire
|
||
|---|---|---|
|
When is a salesman not a salesman? That was the question facing the U.S. Supreme Court on April 16, as it heard oral arguments in Michael Shane Christopher, et al. v. SmithKline Beecham Corporation, d/b/a GlaxoSmithKline, considering whether pharmaceutical sales representatives are outside sales people, exempt from overtime payments required by the Fair Labor Standards Act of Decision. Read More. |
||
|
Trends to Watch
|
||
|
Should Pharma be Interested in Pinterest? Last month, Panorama asked for the industry’s take on Pinterest and its meteoric growth. The responses include Novo Nordisk’s plan for the interest-based social media site, the opinions of marketers on what kind of value the site can have for pharma, and, of course, the regulatory headaches to be aware of. Read More. |
||
|
Click here for the full content from the current issue of Panorama |
||
| HOT TOPICS | |
![]() |
FDA’S SCIENTISTS SAY POLITICAL INFLUENCE ‘TOO HIGH’ Scientists at the FDA feel that despite the agency’s attempts to improve scientific integrity, several areas are still lacking, according to a 33-question survey conducted by the Union of Concerned Scientists (UCS). A total of 997 FDA scientists responded to the survey, with 30% saying that they felt political interests had “a lot of weight in the FDA’s final decisions” and 55% believing that such influence was “too high.” Not all of the findings were negative, however,.… |
| The Scientists’ Take In the same survey conducted by the Union of Concerned Scientists, respondents were also asked to make general comments as well as address specific areas. The scientists did not hold back. On Management and Scientific Development Concerns “There is a serious trend in some disciplines in CDER to overlook the complexity of science as it applies to drug development, to assume that we have complete knowledge of how the human body works and to latch onto simplistic theories and explanations to make safety problems go away.… |
|
To Access ALL of PM360's Experts on Call Click Here! |
![]() |
| FEATURES | |
![]() |
PM360 COVER STORY: Patient Adherence: Initiating the Journey toward Collaboration By Thomas Forissier As healthcare payment systems increasingly emphasize outcomes, stakeholders—manufacturers, providers, pharmacies, and payers—will have to work together to understand the dynamics of patient adherence (and non-adherence) and address them creatively to engage the patient in successful treatment. |
![]() |
EXTENDED ONLINE ARTICLE: Marrying Patients to Adherence Begins with Engagement By Jay H. Bolling Here is a distillation of the learning, approaches and techniques that have significantly increased patient adherence rates over the past 20 years. The greatest success in promoting adherence is realized through applying some core principles of behavioral psychology. |
![]() |
THE EXTENDED BRAND—a Recipe for Success in a Customer-Centric World By Jim McDonough Going beyond the pill to offer value-added services is helping companies from Incyte to Pfizer build brands that patients embrace as caring and trusted partners. |
![]() |
PM360 THINK TANK: The Challenges of Managing Global Brands With Christian Bauman, Nick Colucci, Joe Daley, David Davidovic, Kurt Kessler, Mark Klapper, Richard T. Minoff, Emma Sergeant, David Paragamian We ask industry experts how global brand management is changing and what it takes to manage a global brand. |
![]() |
Automating Business Analytics to Boost Marketing, Sales, and ROI By Dharmendra Sahay and Maria Kliatchko Recent improvements in technology and analytics will help pharmaceutical companies respond to market demand faster than ever before. |
| IN THIS ISSUE |
|
Publisher's Letter Positive Outcomes Guest Commentary Changing the Game…Mike Marett Industry Briefs Washington Wire On Healthcare Reform Douglas McCormick DTC 360 Go Gray Wisely… Richard Meyer Common Sense Establish Yourself as a Product Management Authority Bud Bilanich Healthcare HighlightsFDA Scientists Slam Political Influence, FDA Update, and more E-Source Choosing the Right Technology for Your Content Can Save You Money Ron Scalici Life Style Immune systems need challenges, dumb use of QR codes, and more Market Watch Overactive Bladder Market: Managing the Future Melissa Leonhauser PR360 Keeping it Tweet and Simple Gil Bashe Physician POV Earn a Black Belt in Adherence Stephen R. Feldman, MD, PhD Calendar The quick reference for upcoming industry events Cutting Edge Gadgets and gear for today's on-the-go professional Movers & Shakers Career changes in the industry PhotoFinish Lake Louise, Banff National Park, Alberta |
